Roche's pills are generating a lot of money - but investors think it should be more
Keystone
Basel-based pharmaceutical company Roche released what it considered “strong 2013 results” on Thursday. However, profits and dividend increase were slightly lower than expected.
This content was published on
1 minute
swissinfo.ch and agencies
Roche’s net profits increased 18% in 2013 to CHF11.4 billion ($12.7 billion), falling short of the CHF11.62 billion average forecast by analysts in a Reuters poll.
Driven by strong demand for its cancer and rheumatoid arthritis medicines, Roche’s full-year sales increased 3% to CHF46.78 billion, in line with forecasts.
Roche said it planned to raise dividends 6% to CHF7.80 and expected to further increase the payout in the future. It was the company’s 27th consecutive year of dividend growth. Nevertheless, analysts in the Reuters poll were looking for a dividend of CHF7.98.
Competition
Roche, the world’s largest producer of cancer drugs, had success in 2013 with several medicines it hopes will supplement or replace its older treatments. It hopes these drugs will help it forestall competition from other companies’ cheaper, copycat versions.
Sales of Perjeta, a treatment for women with a particularly aggressive form of breast cancer, rose nearly fivefold to CHF326 million, the company reported.
The company announced it expected sales in 2014 to grow at low- to mid-single-digit rates.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis sustains growth as patents expire
This content was published on
Chief executive Joseph Jimenez said on Wednesday that Novartis delivered a strong performance in 2013, with net sales and core operating income in constant currencies increasing while absorbing patent expirations. Jimenez earned CHF13.23 million for running the company last year. Between them, the 11 members of Novartis’ executive committee received remuneration packages totalling CHF67.7 million…
This content was published on
Finishing its last day of business on December 30 at 8,203 points, the benchmark index reflected a broad rally across European markets with the German DAX up 25%, the French CAC-40 rising 17% and Britain’s FTSE increasing 14% on the year’s trading. Even crisis-hit markets such as those in Ireland and Greece posted strong growth…
This content was published on
Humer, who has been working for the Swiss pharmaceutical company since 1995, announced at the last shareholder meeting that he would not be standing for re-election. From 1998 until 2008 he was Roche’s CEO, and from 2001 onwards he took on the role of chairman. “With Christoph Franz, Roche is getting a chairman with outstanding…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.